Managed Healthcare Executive1h
Gene Therapy’s Pipeline Has a Steady Flow of More Than 2,000 Candidates
The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...
Mammoth Biosciences Announces New Results on NanoCas – the First Efficient Ultracompact Extrahepatic Gene Editor
NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.
Gene therapies have been uneven for DMD — but these companies hope to turn the tide
Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...
GlobalData on MSN8d
Viralgen and Axovia to develop gene therapy for retinal dystrophy
Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...
Gene Transfer Technologies Market to Hit US$5.93 Billion by 2029 with 9.7% CAGR | MarketsandMarkets™
The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of ...
ophthalmologytimes3d
Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...
Pharm Exec8d
Viralgen and Axovia Partner to Manufacture Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome Patients
Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal ...